bacteria, FK037, like cefpirome, demonstrated more potent activity than ceftazidime, cefoperazone and ceftizoxime. It is noteworthy that FK037, on the basis of the MIC90s, was the most active of all the cephalosporins tested against methicillin-resistant Staphylococcus aureus (MRSA). It was similar in activity to cefpirome against methicillin-sensitive S. aureus (MSSA). Against clinical isolates of aerobic Gram-negative bacteria, FK037, like cefpirome, was superior to cefoperazone, similar to ceftazidime and inferior to ceftizoxime in activity. Against P. aeruginosa, FK037 was superior to cefoperazone, similar or slightly superior to cefpirome and inferior to ceftazidime in activity. However, FK037 exhibited significant activity against Citrobacter and Enterobacter which were highly resistant to ceftazidime, cefoperazone and ceftizoxime. FK037had an advantage in that its bactericidal activity against S. aureus, Escherichia coli and P. aeruginosa at sub-MICs (1/2 or 1/4 the MIC) was much stronger than those of cefpirome and ceftazidime. Moreover, it exhibited potent bactericidal activity against MSSA,MRSAand P. aeruginosa in a pharmacokinetic in vitro model simulating human plasma concentrations after intravenous dosage of 0. 125, 1.0 and 1.0 g, respectively. FK037 inhibited essential penicillin-binding proteins (PBPs), 1, 2 and 3 ofS. aureus with a 50% inhibitory concentration (I50) of 0.58jug/ml or lower. Of essential PBPs 3, la and lb of E. coli and P. aeruginosa, FK037 inhibited PBP 3 at the lowest I50 (0.03 and 0.04/ig/ml, respectively) and PBPs la and lb with I50
values of 2.7/ig/ml or lower. FK037, like cefpirome, was highly stable to hydrolysis by various /Mactamases except Ic cephalosporinase from Bacteroides fragilis, and had extremely low affinity for /Mactamases. Therefore, FK037 was more potent than ceftazidime in activity against /Mactamase-producing bacteria except P. aeruginosa and Serratia marcescens. The ability of FK037 to penetrate the outer membraneof E. coli was slightly higher than that of ceftazidime, but slightly lower than that of cefpirome.
Great improvement in antibacterial activity, spectrum and /Mactamase stability has been achieved in the so-called third generation parenteral cephalosporins over the last decade. However, most third generation cephalosporins displayed a weak activity against staphylococci and Pseudomonasaeruginosa. Cefpirome (HR 810), as described by Jones et al}\ is a "fourth generation cephalosporin", due to its enhanced activity against staphylococci, Enterobacteriaceae and P. aeruginosa, when compared to third generation cephalosporins. Wealso recently succeeded in addressing this deficiency of third generation cephalosporins with FK037 ( Fig. 1 ) as evidenced by its in vitro activity against methicillin-resistant Staphylococcus aureus2~5).
The in vitro antibacterial activity of FK037in comparison to that of the reference drugs is the subject of this report. broth plus 5% Fildes enrichment; and anaerobic bacteria in GAMbroth (Nissui). 104cfu/spot were inoculated with a multipoint replicating apparatus onto agar plates containing serial 2-fold dilutions of each antibiotic prior to incubation at 37°C for 18 hours. Incubation was carried out in an atmosphere of 5%GO2for streptococci, H. influenzae, Neisseria species and C. diphtheriae, whereas anaerobic bacteria were incubated in an anaerobic system Model 1024 (Forma) at 37°C for 24hours. The MICwas read as the lowest drug concentration required to inhibit visible growth of the organism. Growth of less than 5 colonies was considered as negative.
Materials and Methods

Determination of MinimumBactericidal Concentration (MBC)
MBCvalues were determined by the microdilution broth method in Mueller-Hinton broth supplemented with CaCl2 at 50mg/liter and MgCl2 at 25 mg/liter. The drugs dissolved in the medium at lOOjUg/ml were serially diluted 2-fold with an automatic diluter AD-2 (Dainippon Seiki), and 100/il of each broth was dispersed into 96-well multiwell trays with a dispenser (MIC 2000 system; Dynatech). The strains precultured on Mueller-Hinton agar at 37°C for 18hours were suspended in saline for turbidity adjustment to McFarland 0.5 standard. About 1 /xl samples of the suspension were inoculated into broths containing drugs with an automatic inoculator (MIC 2000 system; Dynatech) to achieve a final concentration at about 106cfu/ml. After incubation at 37°C for 18 hours, the MICwas read as the lowest drug concentration that inhibited visible bacterial growth. About lp\ of the culture broth in each well was inoculated onto Mueller-Hinton agar with an automatic inoculator. Media for Proteus species contained 3%agar to prevent swarming on the agar surface. After incubation at 37°C for 18 hours, the MBCwhich killed 99.9% of inoculated bacteria was read as the lowest drug concentration that inhibited colony formation.
Bactericidal Activity at Constant Concentrations
Overnight cultures of S. aureus 209P JC1 in Trypticase soy broth (BBL), and Escherichia coli NIHJ JC2 and P. aeruginosa 7001 in Mueller-Hinton broth were diluted in fresh Mueller-Hinton broth to achieve a final concentration of about 106 cfu/ml prior to incubation with shaking at 37°C for 1 hour. The bacteria were then exposed to drugs at 1/4 to the MICat 37°C, and the viable bacterial counts were determined after incubation for 2, 4 or 6hours. MICs were determined by the macrodilution broth method in the same volume of culture with the time-kill study after incubation for 18 hours.
Bactericidal Activity in an In Vitro Pharmacokinetic Model Overnight cultures in Mueller-Hinton broth were diluted in the same fresh media to a final concentration of 106cfu/ml and incubated with shaking at 37°C for 1 hour. The bacteria were then exposed to drugs at the estimated human plasma concentrations achieved after intravenous dosing of 0.125g to 1.0g, concentrations which were achieved by a stepwise dilution with fresh mediumas described by Nishida6). The human plasma concentrations of FK037were calculated on the basis of the data on healthy volunteers receiving intravenous FK037 (0. 125 g)7), whereas those of cefpirome, ceftazidime and flomoxef were referred to previously published data8~10). Viable cells were counted at various time intervals and adjusted by dilution factors.
Affinity to Penicillin-binding Proteins (PBPs) PBP assays were performed by the modified method of Spratt11>12). Membrane fractions containing PBPs were prepared from bacteria after sonication with a sonicator Model 200M(Kubota) and ultracentrifugation at 100,000 x g. For preparation of membrane fractions from S. aureus, lysostaphin (Sigma) treatment at 50jug/ml at 30°C for 30minutes was performed before sonication. The membrane fractions from various strains were exposed to drugs at 30°C for 10 minutes. 14C-Labeled benzylpenicillin (14C-PCG, specific activity at 58.5 mCi/mmol, Amersham) was used for detection of unsaturated PBPs by pretreatment with drugs. The labeled PBPs were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) with 10% acrylamide and 0.12% bisacrylamide. The gels were processed for fluorography and the concentrations of drugs which inhibited the 14C-PCGbinding to 50%of non-treated PBPs (I50) were determined as the affinity of drugs to PBPs after scanning the X-ray film with a densitometer
Model CS-930 (Shimadzu).
/?-Lactamase Assay THE JOURNAL OF ANTIBIOTICS JAN. 1993 After disruption by sonication, /Mactamases from several strains were purified by gel filtration via a Sephadex G-100 column. Enzymatic hydrolysis rates of drugs were determined with a spectrophotometer Model UV-265FW(Shimadzu) at 37°C in a 67him phosphate buffer (pH 7.0). The extinction coefficients per 1 cm at 50^g/ml used were as follows; The permeability coefficients of FK037, cefpirome and ceftazidime in E. coli FP1719 (TEM-9-/Mactamase producing strain) were determined by the method of Zimmermannand Rosselet13).
Results
Antibacterial
Spectrum of FK037
The activities of FK037 against 43 stock strains of aerobic organisms are shown in Table 1 . FK037 had potent antibacterial activity against an extensive range of organisms, including staphylococci and P. aeruginosa. This antibacterial activity was similar to that of cefpirome, except that it was less active against E. faecalis. FK037 was more potent than ceftazidime against most Gram-positive bacteria and Gram-negative bacteria, however, it was less active against glucose-nonfermenting organisms including P. aeruginosa. Further, FK037was superior and equipotent to ceftizoxime against most Gram-positive bacteria and Gram-negative bacteria, respectively. FK037 was moreactive than ceftizoxime against P. aeruginosa and Pseudomonas putida. In addition, FK037 displayed a potent activity against Gram-positive and Gram-negative anaerobic organisms (Table 2) . Its activity approximated to that of cefpirome, was greater than that of ceftazidime, but was weaker than that of ceftizoxime.
Antibacterial Activity of FK037 against Clinical Isolates The activities of FK037against various clinical isolates were comparedwith those of cefpirome, ceftazidime, cefoperazone, ceftizoxime, flomoxef and cefuzonam. Table 3 shows the drug concentration necessary to inhibit 50%or 90%of the test strains and the MICrange. FK037displayed advantages over ceftazidime, cefoperazone and ceftizoxime in its activities against S. aureus and coagulase-negative staphylococci. In addition, the MIC90 of FK037 (25 /zg/ml) was the lowest of all the cephalosporins tested (except flomoxef) against MRSAand MRCNS.However, the activity ofFK037 against MSSAand MSCNS was similar or slightly inferior to those ofcefpirome, flomoxef and cefuzonam. FK037, like the other drugs except cefpirome and cefoperazone, was not active against E. faecalis. Against most clinical isolates of Gram-negative bacteria, FK037 had excellent in vitro activity similar to that of cefpirome, superior to those of ceftazidime, flomoxef and cefoperazone, and inferior to that of ceftizoxime. It is noteworthy that the MIC90sof FK037, like cefpirome, against Citrobacterfreundii and Enterobacter species were less than 3.13 /zg/ml, whereas those of ceftazidime, cefoperazone, flomoxef and ceftizoxime were 25^g/ml or higher. FK037was also active against P. aeruginosa, and its activity was superior to that of cefoperazone, slightly superior to cefpirome, and slightly inferior to ceftazidime. and cefoperazone. Against ampicillin-resistant N. gonorrhoeae and H. influenzae, FK037, like the reference drugs, had an excellent activity. However, the activity of FK037 and the reference drugs was lower against ampicillin-resistant S. pneumoniae than that against ampicillin-sensitive S. pneumoniae. FK037exhibited potent activities against cefoperazone-resistant Gram-negative bacteria except Enterobacter aerogenes, Xanthomonas maltophilia and P. aeruginosa. The activity of FK037 against these organisms was equipotent to that of cefpirome. Against ceftazidime-resistant Gram-negative bacteria, FK037demonstrated potent activities against C. freundii and Enterobacter species, and moderate activities against Flavobacterium meningosepticum and Acinetobacter calcoaceticus. However, it was inactive against Serratia marcescens, X. maltophilia, P. aeruginosa and Alcaligenes denitrificans subsp. xylosoxydans. The mean MICs of FK037 against several Gram-negative strains producing one or two /Mactamases were compared with those of cefpirome, ceftazidime and cefoperazone (Table 5 ). FK037 had potent activity against the strains producing TEM-1 PCase, IV PCase, la CSase, Ib CSase, TEM-1 PCase+Ia CSase (except S. marcescens) and TEM-1PCase+Ib CSase, and a moderate activity against the P. aeruginosa strains producing PSE-1 and OXA-2 PCase and the S. marcescens strains producing la CSase and TEM-1 PCase+la CSase. However, it had poor activity against P. aeruginosa strains producing Id CSase. The activity of FK037 against these strains was similar to that of cefpirome; FK037was slightly better vs. OXA-2PCase and slightly less vs. la CSase. FK037 had more potent activity than ceftazidime against all strains except the CSase producers of P. aeruginosa and S. marcescens. Similarly, FK037was more potent than cefoperazone against all strains except the OXA-2PCase producing P. aeruginosa.
Comparison Agar dilution method (stamp method): Mueller-Hinton agar, 104cfu/spot, 37°C, 18 hours; a supplement with 5% defibrinated horse blood (cchocolate agar), 5% CO2; bGAMagar (Nissui), Anaerobic system model 1024 (Forma), 37°C, 24 hours.
are shown in Table 6 . The mean MBCsof FK037 were similar to the mean MICs against all organisms tested except S. marcescens. The mean MBCsof FK037 against MSSA,S. epidermidis and Gram-negative bacteria except S. marcescens and P. aeruginosa ranged from 0.1 to 1.56jUg/ml and were equipotent to (5) (^1.56/^g/ml) Neisseria gonorrhoeae (7) (^6.25^g/ml) Haemophilus influenzae (8) (^6.25 /zg/ml) Cefoperazone-resistant (^25 Mg/ml)d
Proteus vulgaris (2) Serratia marcescens (19) Citrobacter freundii ( 1) Enterobacter cloacae (1) E. aerogenes (1) Xanthomonas maltophilia (5) Pseudomonas aeruginosa (1 1 8) P. cepacia (1 1 those of cefpirome, but superior to those of flomoxef, ceftazidime and cefoperazone. Against L-MRSA and H-MRSA, the mean MBCsof FK037 were 14.4 and 25/ig/ml, respectively, but superior to those of the other tested drugs. FK037,like cefpirome, was more active than the other drugs against S. marcescens. The mean MBCof FK037against P. aeruginosa was equipotent to that of cefoperazone, superior to that of cefpirome and flomoxef, but inferior to that of ceftazidime.
Bactericidal Activity of FK037
Bactericidal Activity at Constant Concentrations Against S. aureus 209P JC1 (Fig. 2) , FK037 had bactericidal activity even at concentrations of 1/4 the MICand 1/2 the MIC. The activity of FK037 was more potent than that of cefpirome and ceftazidime. Klebsiella pneumoniae (7) Serratia marcescens (4) Pseudomonasaeruginosa (6) Pseudomonasaeruginosa (2) Klebsiella pneumoniae (7) Citrobacter freundii (12) Enterobacter cloacae (12) Serratia marcescens (4) Escherichia coli (6) Pseudomonas aeruginosa (5) Citrobacter freundii (3) Enterobacter cloacae (1) Serratia marcescens (4) Escherichia coli (2) Pseudomonas aeruginosa (1) Pseudomonas aeruginosa (1) Against E. coli NIHJ JC2 (Fig. 3) , FK037, like cefpirome and ceftazidime, elicited excellent bactericidal activity at 1/2 the MIC or higher. Against P. aeruginosa 7001 (Fig. 4) , the bactericidal activity of FK037 was relatively superior to those of cefpirome and ceftazidime.
Bactericidal Activity in an In Vitro Pharmacokinetic Model To estimate the drug efficacy in humansubjects, bactericidal activity was also studied in an in vitro pharmacokinetic model simulating human plasma concentrations after an intravenous dosage of 0.125 g against MSSA,and 1.0g against MRSAand P. aeruginosa (Fig. 5) . Against S. aureus 2562M2 (MSSA), (A) FK037 (MIC: 0.05 /ig/ml), (B) cefpirome (MIC: 0.05 /ig/ml), (C) ceftazidime (MIC: 0.2/ig/ml).
FK037, even at 0.125 g, was highly bactericidal during the 8hour-incubation, although its activity was slightly lower than that offlomoxef. Against S. aureus 5027 (MRSA), FK037 showed an excellent bactericidal activity even at 1.0g dose. However, cefpirome and flomoxef at 1.0g doses showed only bacteriostatic activity for 3 hours followed by regrowth. Against P. aeruginosa 7129, FK037, even at 1.0g, was highly bactericidal for the 8 hours incubation. Its bactericidal activity was similar to that of ceftazidime. However, regrowth of P. aeruginosa occurred 4 hours after incubation with cefpirome. 14C-PCG binding by 50%. As shown in Table 7 , FK037 inhibited PBPs 1, 2 and 3 of S. aureus at I50 values of 0.58 //g/ml or lower, which is similar to that of cefpirome and flomoxef, although FK037 and cefpirome were inferior to flomoxef in PBP 4 affinity. Against the main PBPs of E. coli, FK037 inhibited PBP 3 to the greatest extent (I50 0.03 //g/ml), which is similar to that obtained with cefpirome, flomoxef and ceftazidime. PBPs lbs and la were inhibited at 1.5 and 2.7/jg/ml ofFK037, respectively. The inhibition of PBP lbs by FK037 is similar to ceftazidime and inferior to cefpirome and flomoxef, while against PBP la, FK037 had greater inhibition than cefpirome and inferior inhibition to that of flomoxef and ceftazidime. FK037 inhibited the PBP 3 of P. aeruginosa at the I50 value of 0.04/ig/ml, PBP la at 0.08//g/ml and PBP lb at 2.7/zg/ml. The affinities of FK037to the main PBPs of P. aeruginosa were nearly equipotent to those of cefpirome and ceftazidime.
Stability
and Affinity of FK037 to Various /?-Lactamases Relative Vmax,Kmand Vmax/Km values ofFK037 for various /Mactamases were compared with those of cefpirome, ceftazidime and cefoperazone (Table 8) . Based on these values, FK037 was stable to CSase and PCase, but was unstable to Ic CSase from Bacterioidesfragilis.
The stability of FK037to these enzymes was markedly superior to that of cefoperazone and similar to that of cefpirome, except for IV and OXA-2 PCase, where FK037was more stable, and la CSase from Enterobacter cloacae where FK037was less stable than cefpirome. Except for Ib CSase, FK037was less stable than ceftazidime to all the CSases. Based on the Kmvalues, FK037had similar affinities as cefpirome to the /?-lactamases. Whencompared with ceftazidime, the affinities of FK037 were lower for la CSase (E. cloacae) and Ib CSase, but higher Method of Zimmermannand Rosselet.
Discussion
FK037 displayed a broader spectrum of activity than the so-called third generation cephalosporins such as ceftazidime, cefoperazone and ceftizoxime, and its spectrum of activity was similar to that of cefpirome. A major improvement of FK037 over the third generation cephalosporins was the increased anti-staphylococcal activity. In particular, the improved activity of FK037against MRSAis one of its major characteristics. The anti-staphylococcal activity of FK037 can be attributed to its high affinity for PBPs 1, 2 and 3 of S. aureus, and PBP 2a of MRSA4).The detailed anti-MRSA activity of FK037 will be presented in another paper14). The anti-pseudomonal activity is another major attribute of FK037. The activity of FK037 was slightly better than cefoperazone and cefpirome but inferior to ceftazidime..Although the affinities of FK037to PBPs3, la and 1b ofP. aeruginosa were nearly equipotent to those ofceftazidime, FK037 MICs were higher than those of ceftazidime. This discrepancy may be based on the poorer stability ofFK037 to pseudomonal /Mactamases or its poorer outer membranepermeability compared to ceftazidime. In addition, the potent activity of FK037against C. freundii and Enterobacter species resistant to most third generation cephalosporins may also be related to higher stability to /Mactamases, its higher affinity to essential PBPs and its more efficient outer membranepermeability. The high /Mactamase stability of FK037 was due to low Vmax and high Kmvalues, indicating that FK037 can not be easily recognized and degraded by most /?-lactamases. On the basis of its antibacterial profiles, FK037, like cefpirome, should be considered a "fourth generation cephalosporin" as described by Jones et al}\ The MBCsof FK037 were similar to the MICsagainst the various bacterial species tested except S. marcescens. In particular, it is noteworthy that the MBCsof FK037 against both L-and H-MRSA(14.4 and 25 //g/ml, respectively) were the lowest among the cephalosporins tested. Potent bactericidal activity of FK037 by time-kill studies was noted even at a concentration of 1/2 or 1/4 the MICagainst S. aureus, E. coli and P. aeruginosa, which was superior to that of cefpirome and ceftazidime except against E. coli. These results suggest that the bactericidal activity of FK037 is more potent than could be anticipated from the MICs, especially against MRSA and P. aeruginosa. In an in vitro pharmacokinetic model simulating human plasma concentrations after an intravenous dose, FK037 showed excellent bactericidal activity for 8 hours against MRSA(MIC 25^g/ml) after administration ofa 1.0 g dose in this model. Cefpirome and flomoxef showed only bacteriostatic activity up to 3 hours after which bacterial regrowth occurred. In addition, FK037even at a 1.0g dose was bactericidal against P. aeruginosa (MIC 25/zg/ml) up to 8 hours after administration. It was as potent as ceftazidime and superior to cefpirome which exhibited the bacterial re-growth 3 hours after administration. The excellent bactericidal activities of FK037in this system suggest that FK037might be useful for treating MRSA and pseudomonal infections in humans.
From these results, clinical application of FK037may be expected in patients with infections caused by a wide range of pathogenic bacteria.
